Mortality rates and disability-adjusted life years (DALYs) rates by disease stage, sex, and age groups (<35, 35–49, 50–69, ≥ 70, and all ages) in China from 1990 to 2021. by Xinyue Qi (9637055)

Subjects:

Decomposition analysis of changes in hepatitis B virus (HBV) burden by region (China vs. Global), sex, and disease stage, 1990–2021. by Xinyue Qi (9637055)

Subjects:

Temporal trends of mortality of the total burden related to hepatitis B and three disease stages for all ages and across four age groups (<35, 35–49, 50–69, and ≥ 70 years) from 19... by Xinyue Qi (9637055)

Subjects:

Age patterns by sex of the total number and age-specific death rates in 2021. by Xinyue Qi (9637055)

Subjects:

Age-standardized mortality rates (ASMR), age-standardized disability-adjusted life year rates (ASDR), and their 95% uncertainty intervals (UIs) by disease stage in China from 1990... by Xinyue Qi (9637055)

Subjects:

BAPC model projections of mortality and DALYs rates for each disease stage in China from 2022 to 2035, with 50%, 60%, 70%, 80%, and 95% uncertainty intervals. by Xinyue Qi (9637055)

Subjects:

Temporal trends of DALYs of the total burden related to hepatitis B and three disease stages for all ages and across four age groups (<35, 35–49, 50–69, and ≥70 years) from 1990 to... by Xinyue Qi (9637055)

Subjects:

Decomposition analysis of changes in hepatitis B virus (HBV) burden by region (China vs. Global), sex, and disease stage, 1990 to 2021 (in Thousands). by Xinyue Qi (9637055)

Subjects:

Predictions for the annual age-standardized disability-adjusted life years (ASDR) attributable to hepatitis B virus (HBV) infection in China until 2035 on the basis of the Bayesian... by Xinyue Qi (9637055)

Subjects:

This diagram summarizes the main steps of our study, including data sourcing from the GBD 2021 database, stratified processing by disease stage, age, and sex, application of EAPC a... by Xinyue Qi (9637055)

Subjects:

The global prevalence of gynecological diseases among women aged 15-49 years in 1990 and 2021, along with the trends and changes observed between these years. by Xiaofeng He (2618752)

Subjects:

Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations. by Denis Mustafov (19137870)

“…<b>(D)</b> Similarly, U251MG cells showed significantly decreased clonogenic potential upon 100ΜM SHG-44 treatment when compared to 100ΜM cis-platin and the untreated control. …”

Sex differences and percentage change trends in smoking-attributable RA burden from 1990 to 2021. by Kaibin Lin (9911049)

Subjects:

Significant condition. by Junxia Zhou (14381598)

Subjects:

EAPC in incidence and mortality of LC for age group. by Ze-Xing Zhang (18074512)

Subjects:

Cases and deaths of LC from the Chinese Annual Cancer Registry, 2004–2018. by Ze-Xing Zhang (18074512)

Subjects:

Changes in LC cases and deaths in male and female from 2004 to 2018, decomposed by three population-level determinants: population aging, population growth and epidemiological chan... by Ze-Xing Zhang (18074512)

Subjects:

Projected ASIR and ASMR of LC in China over the next 15 years based on the Bayesian APC model. by Ze-Xing Zhang (18074512)

Subjects:

The incidence and mortality data of LC by age group from the Chinese Annual Cancer Registry, 2004–2018. by Ze-Xing Zhang (18074512)

Subjects:

Contribution of changes in population aging, population growth, and age-specific incidence rate to changes in incident cases of LC from 2004 to 2018 in China. by Ze-Xing Zhang (18074512)

Subjects: